Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735799 | 1.00 | SLC1A3 (0.64) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL334926 | 1.00 | SLC1A3 (0.64) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL11317170 | 0.91 | HTT (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2139878 | 0.91 | HTT (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2139876 | 0.91 | HTT (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL6827224 | 0.90 | HTT (0.63) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL318936 | 0.90 | HTT (0.63) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL318935 | 0.90 | HTT (0.63) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL6827355 | 0.89 | TGM2 (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL6827174 | 0.89 | TGM2 (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716856-A | Method for synthesizing aminoglycoside antibiotic arbekacin | 山东厚德精诚药业有限公司 | 2023-02-28 | — | — | CN | claimed |
| US-5656735-A | Process for the preparation of amikacin precursors | BIOCHIMICA OPOS SPA (IT) | 1997-08-12 | — | — | US | claimed |
| EP-0446670-B1 | Method of preparation of amikacin precursors | OPOS BIOCHIMICA SRL (IT) | 1994-09-21 | — | — | EP | claimed |
| EP-0446670-A1 | Method of preparation of amikacin precursors | BIOCHIMICA OPOS SPA (IT) | 1991-09-18 | — | — | EP | claimed |
| US-4268664-A | Process for the preparation of 1-N-isoseryl- or 1-N-(L-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B and intermediates thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1981-05-19 | — | — | US | claimed |
| CN-120719568-A | Environment-friendly newsprint and preparation method thereof | 河北华泰纸业有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-115716856-B | Synthetic aminoglycoside method for antibiotic Abecamycin | 北京耀诚惠仁科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-11932633-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-115716856-A | Method for synthesizing aminoglycoside antibiotic arbekacin | 山东厚德精诚药业有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20210380570-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-12-09 | — | — | US | disclosed |
| EP-3790551-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-4065616-A | ANTIBIOTICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-12-27 | — | — | US | disclosed |
| US-4065615-A | Deoxyaminoglycoside antibiotic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-12-27 | — | — | US | disclosed |
| US-4055715-A | Method of producing 1-N-[L-(-)-α-hydroxy-γ-aminobutyryl]XK-62-2 | ABBOTT LABORATORIES (US) | 1977-10-25 | — | — | US | disclosed |
| US-4038478-A | ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4001208-A | DERIVATIVE OF AN AMINOGLYCOSIDIC ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYO KAI (JA) | 1977-01-04 | — | — | US | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3940382-A | BACTERICIDE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380570-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SLC1A3 3382/4885SLC1A1 3969/4885LMNA 2991/4885 |
| US-11932633-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SLC1A3 3382/4885SLC1A1 3969/4885LMNA 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.